Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has granted fast track designation to PSV359, a targeted alpha radiopharmaceutical, for adults with locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors. The therapy pairs lead-203 imaging with lead-212 treatment to precisely identify and attack tumors. Early phase 1/2a trial data show a favorable safety profile with no dose-limiting toxicities so far.
The FDA has granted fast track designation to [²¹²Pb]PSV359, a targeted alpha radiopharmaceutical developed by Perspective Therapeutics, for adult patients with locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors — a rare and aggressive cancer with no currently approved FAP-α–targeted therapies.
PSV359 works by pairing lead-203 for SPECT/CT imaging with lead-212 for alpha-particle therapy, allowing clinicians to first confirm FAP-α expression in a patient's tumor before delivering precision radiation treatment. FAP-α is broadly expressed across many solid tumors and within the tumor microenvironment, making it an attractive target across multiple cancer types.
Key Takeaways:
Why it matters: Solitary fibrous tumors are rare and notoriously difficult to treat, and FAP-α–targeted therapies represent a completely new therapeutic avenue. Fast track designation will accelerate PSV359's development pathway, potentially bringing a first-in-class treatment option to patients with very limited alternatives.
